MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2024
0mins
Source: businesswire
- MM120 Study Results: Mind Medicine (MindMed) presented data from its Phase 2b study of MM120 in treating Generalized Anxiety Disorder (GAD) at the APA Annual Meeting, showing significant efficacy compared to placebo.
- Clinical Findings: MM120 demonstrated rapid and sustained improvements in anxiety symptoms, with a 100µg dose showing optimal clinical activity and positive outcomes at Week 12.
- Secondary Endpoints: The study also assessed secondary endpoints like Montgomery-Åsberg Depression Rating Scale (MADRS) scores, indicating significant improvements in depressive symptoms.
- Safety and Tolerability: MM120 was generally well-tolerated, with mild to moderate adverse events occurring on dosing day, aligning with expected acute effects of the drug.
- Epidemiological Studies: Additional studies highlighted the underdiagnosis of GAD and its impact on individuals' quality of life, healthcare utilization, and work productivity loss.
Analyst Views on MNMD
Wall Street analysts forecast MNMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNMD is 31.11 USD with a low forecast of 18.00 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.020
Low
18.00
Averages
31.11
High
61.00
Current: 15.020
Low
18.00
Averages
31.11
High
61.00
About MNMD
Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. It also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
